Researchers develop system to manufacture range of bio-pharmaceuticals on demand

02 Aug 2016

1

Researchers have developed a production system capable of manufacturing a range of bio-pharmaceuticals on demand to help doctors treat patients in remote or developing parts of the world like India, where getting rapid access to drugs could be challenging.

Bio-pharmaceutical drugs were used in a wide range of therapies including vaccines and treatments for diabetes and cancer, but these were typically produced in large, centralised fermentation plants and transporting them to the treatment site could be expensive and time-consuming.

With the new system, developed by researchers at the Massachusetts Institute of Technology, it was possible to produce a single dose of treatment from a compact device containing a small droplet of cells in a liquid.

A recent issue of the journal Nature, carried a description of the system.

"Imagine you were on Mars or in a remote desert, without access to a full formulary, you could program the yeast to produce drugs on demand locally," said senior study author Tim Lu, IANS reported.

It is also possible to carry the system onto the battlefield to produce treatments at the point of care.

It can also be used to produce a vaccine to prevent a disease outbreak in a remote village.

The system is based on a programmable strain of yeast, Pichia pastoris, which could be induced to express one of two therapeutic proteins when exposed to a particular chemical trigger, according to researchers.

"We altered the yeast so it could be more easily genetically modified, and could include more than one therapeutic in its repertoire," said Lu, PTI reported.

Latest articles

Bank of America Profit Rises as Market Volatility Boosts Trading Revenue

Bank of America Profit Rises as Market Volatility Boosts Trading Revenue

State Street to Acquire 23% Stake in Groww AMC for ₹580 Crore

State Street to Acquire 23% Stake in Groww AMC for ₹580 Crore

Retail Investors Surge into Memory Chip Stocks as AI Demand Tightens Supply

Retail Investors Surge into Memory Chip Stocks as AI Demand Tightens Supply

NLC India Seals ₹25,000 Crore Green Energy Pact with Gujarat; Board Clears NIRL IPO

NLC India Seals ₹25,000 Crore Green Energy Pact with Gujarat; Board Clears NIRL IPO

India’s Gig Economy Reset: The End of ‘10-Minute Delivery’ Hype?

India’s Gig Economy Reset: The End of ‘10-Minute Delivery’ Hype?

AI Is Becoming the New Electricity Crisis: Why the Real Bottleneck Is Megawatts

AI Is Becoming the New Electricity Crisis: Why the Real Bottleneck Is Megawatts

Toyota Raises Bid for Toyota Industries to ¥18,800 After Investor Pushback

Toyota Raises Bid for Toyota Industries to ¥18,800 After Investor Pushback

AI-Driven Memory Crunch Raises Smartphone Cost Pressure; OPPO Bets on ‘Value-First’ Strategy

AI-Driven Memory Crunch Raises Smartphone Cost Pressure; OPPO Bets on ‘Value-First’ Strategy

Swiggy, Zepto and Blinkit Drop “10-Minute” Delivery Branding After Government Safety Push

Swiggy, Zepto and Blinkit Drop “10-Minute” Delivery Branding After Government Safety Push

Business History Videos

History of hovercraft Part 3 | Industry study | Business History

History of hovercraft Part 3...

Today I shall talk a bit more about the military plans for ...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of hovercraft Part 2 | Industry study | Business History

History of hovercraft Part 2...

In this episode of our history of hovercraft, we shall exam...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Hovercraft Part 1 | Industry study | Business History

History of Hovercraft Part 1...

If you’ve been a James Bond movie fan, you may recall seein...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Trams in India | Industry study | Business History

History of Trams in India | ...

The video I am presenting to you is based on a script writt...

By Aniket Gupta | Presenter: Sheetal Gaikwad

view more
View details about the software product Informachine News Trackers